Citius Oncology Statistics
Total Valuation
Citius Oncology has a market cap or net worth of $73.11 million. The enterprise value is $73.56 million.
Important Dates
The last earnings date was Friday, May 15, 2026, after market close.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Citius Oncology has 88.28 million shares outstanding. The number of shares has increased by 20.32% in one year.
| Current Share Class | 88.28M |
| Shares Outstanding | 88.28M |
| Shares Change (YoY) | +20.32% |
| Shares Change (QoQ) | +14.37% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 1.39% |
| Float | 13.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.53 |
| PS Ratio | 12.90 |
| Forward PS | 1.18 |
| PB Ratio | 2.19 |
| P/TBV Ratio | 2.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.50, with a Debt / Equity ratio of 0.11.
| Current Ratio | 0.50 |
| Quick Ratio | 0.06 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -146.59 |
Financial Efficiency
Return on equity (ROE) is -119.90% and return on invested capital (ROIC) is -69.29%.
| Return on Equity (ROE) | -119.90% |
| Return on Assets (ROA) | -28.31% |
| Return on Invested Capital (ROIC) | -69.29% |
| Return on Capital Employed (ROCE) | -103.90% |
| Weighted Average Cost of Capital (WACC) | 23.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.06 |
Taxes
In the past 12 months, Citius Oncology has paid $561,510 in taxes.
| Income Tax | 561,510 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.37% in the last 52 weeks. The beta is 3.57, so Citius Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 3.57 |
| 52-Week Price Change | -8.37% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 44.18 |
| Average Volume (20 Days) | 104,761 |
Short Selling Information
The latest short interest is 655,066, so 0.74% of the outstanding shares have been sold short.
| Short Interest | 655,066 |
| Short Previous Month | 934,868 |
| Short % of Shares Out | 0.74% |
| Short % of Float | 5.03% |
| Short Ratio (days to cover) | 4.38 |
Income Statement
In the last 12 months, Citius Oncology had revenue of $5.61 million and -$42.51 million in losses. Loss per share was -$0.50.
| Revenue | 5.61M |
| Gross Profit | 4.49M |
| Operating Income | -43.52M |
| Pretax Income | -41.95M |
| Net Income | -42.51M |
| EBITDA | n/a |
| EBIT | -43.52M |
| Loss Per Share | -$0.50 |
Full Income StatementBalance Sheet
The company has $2.63 million in cash and $3.80 million in debt, with a net cash position of -$1.17 million or -$0.01 per share.
| Cash & Cash Equivalents | 2.63M |
| Total Debt | 3.80M |
| Net Cash | -1.17M |
| Net Cash Per Share | -$0.01 |
| Equity (Book Value) | 35.27M |
| Book Value Per Share | 0.38 |
| Working Capital | -29.39M |
Full Balance SheetCash Flow
| Operating Cash Flow | -16.68M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 80.07% |
| Operating Margin | -775.60% |
| Pretax Margin | -747.56% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Citius Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.32% |
| Shareholder Yield | -20.32% |
| Earnings Yield | -58.72% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Citius Oncology is $6.00, which is 624.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 624.46% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
